Of note, exploratory data from a large randomized trial has provided evidence that in subjects with high CRP, yet otherwise healthy, inhibition of IL-1β by canakinumab, reduced the incidence of lung cancer, as well as the lung cancer related mortality. Here, IL1B is linked to lung carcinoma.